Clinical Trial Update: A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating Odalasvir and AL-335 alone and in combination with Simeprevir in participants with moderately impaired hepatic function has been with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Disease

Drugs mentioned

• AL-335 (AL-335)
• Odalasvir (odalasvir)
• Simeprevir (simeprevir)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Hepatic Impairment | Phase 1 | Status: WITHDRAWN